<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7102570\results\search\testTrace\results.xml">
  <result pre="viral load. Favipiravir cures all mice in a lethal influenza" exact="infection" post="model, while oseltamivir fails to cure the animals. Thus,"/>
  <result pre="models with lethal RNA viruses and has been used for" exact="treatment" post="of human infection with life-threatening Ebola virus, Lassa virus,"/>
  <result pre="RNA viruses and has been used for treatment of human" exact="infection" post="with life-threatening Ebola virus, Lassa virus, rabies, and severe"/>
  <result pre="and varicella-zoster infection, and individual antiviral agents target one viral" exact="infection" post="caused by one virus or two viruses of the"/>
  <result pre="in Japan and US, and favipiravir was approved as a" exact="treatment" post="for novel or re-emerging influenza viruses in Japan in"/>
  <result pre="addition to influenza in Japan. Favipiravir was highlighted as a" exact="treatment" post="during the lethal Ebola virus epidemic in West Africa"/>
  <result pre="virus epidemic in West Africa in 2014 because a standard" exact="treatment" post="for lethal Ebola virus infection is not available. Favipiravir"/>
  <result pre="in 2014 because a standard treatment for lethal Ebola virus" exact="infection" post="is not available. Favipiravir has been reported to be"/>
  <result pre="to be effective for prophylaxis and treating lethal Ebola virus" exact="infection" post="in animal models (Oestereich et al., 2014; Smither et"/>
  <result pre="2014; Smither et al., 2014) and is licensed for influenza" exact="treatment" post="based on its confirmed safety and efficacy in clinical"/>
  <result pre="information, favipiravir was successfully used for the post-exposure prophylaxis and" exact="treatment" post="of patients with Ebola virus infection (Bai et al.,"/>
  <result pre="the post-exposure prophylaxis and treatment of patients with Ebola virus" exact="infection" post="(Bai et al., 2016; Jacobs et al., 2015; Sissoko"/>
  <result pre="drugs are expected to play a central role in the" exact="treatment" post="of lethal influenza pandemic and other severe RNA virus"/>
  <result pre="Japan and the US, and favipiravir was approved as a" exact="treatment" post="for novel or re-emerging influenza viruses in Japan in"/>
  <result pre="shown in Table 1 . Patients with an Ebola virus" exact="infection" post="in West Africa in 2014 and patients with other"/>
  <result pre="WHO, dWestern equine encephalitis (Spickler, 2017), eArgentine hemorrhagic fever virus" exact="infection" post="(Enria &amp;amp; Maiztegui, 1994), fChikungunya (Cardona-Ospina, Henao-SanMartin, Paniz-Mondolfi, &amp;amp;"/>
  <result pre="and gWest Nile fever (Philpott et al., 2019). 2.3 Influenza" exact="infection" post="model We have identified two antipyretic steps in influenza"/>
  <result pre="in influenza infections, as shown in Fig. 2 . Influenza" exact="infection" post="and its replication in the epithelium of the upper"/>
  <result pre="influenza and antipyretic action of cinnamyl compounds and NSAIDs. Influenza" exact="infection" post="induces interferon (IFN) production that subsequently induces interleukin (IL)-1"/>
  <result pre="favipiravir were conducted in mice and ferrets using the influenza" exact="infection" post="system described above in our laboratory. 2.4 Efficacy of"/>
  <result pre="in influenza-infected animals Since our laboratory had established an influenza" exact="infection" post="model to investigate the cytokine cascade that induces fever"/>
  <result pre="Oral administration of favipiravir was significantly effective in alleviating influenza" exact="infection" post="in mice (Furuta et al., 2002), and its efficacy"/>
  <result pre="of efficacy between favipiravir and oseltamivir in the influenza virus" exact="infection" post="model established with a high titer of virus in"/>
  <result pre="was observed in an animal with a severe lethal influenza" exact="infection" post="with a high viral load (Takahashi et al., 2003)."/>
  <result pre="on day 3 after a high-dose infection, and an oseltamivir" exact="treatment" post="prolongs the survival period for three days but does"/>
  <result pre="for three days but does not prevent death. The favipiravir" exact="treatment" post="cures lethal infection, and all mice survive. Favipiravir exhibits"/>
  <result pre="delayed administration beginning 1, 24, 48, or 72Â h after" exact="infection" post="with seasonal influenza A(H1N1) (Takahashi et al., 2003). Fig."/>
  <result pre="al., 2003). Mice infected with a low titer represent nonlethal" exact="infection" post="models and are considered to correspond to human seasonal"/>
  <result pre="infection models and are considered to correspond to human seasonal" exact="infection" post="models. In this model, oseltamivir and favipiravir are equally"/>
  <result pre="despite the difference in their mechanisms of action. A high-titer" exact="infection" post="represents a lethal infection model and is considered to"/>
  <result pre="their mechanisms of action. A high-titer infection represents a lethal" exact="infection" post="model and is considered to correspond to a novel"/>
  <result pre="model and is considered to correspond to a novel influenza" exact="infection" post="in humans. Although oseltamivir is ineffective in this model,"/>
  <result pre="2019; Wong et al., 2009), respectively, in infected cells. Influenza" exact="infection" post="induces TNF-Î± production in mouse macrophage-derived P388D1 cells, and"/>
  <result pre="mechanism may also contribute to the enhanced effects of favipiravir" exact="treatment" post="on alleviating influenza infection compared with oseltamivir treatment. Favipiravir"/>
  <result pre="to the enhanced effects of favipiravir treatment on alleviating influenza" exact="infection" post="compared with oseltamivir treatment. Favipiravir displays superior properties to"/>
  <result pre="efficacy in humans and its possible use as the standard" exact="treatment" post="of choice for influenza in the future. 3 Mechanisms"/>
  <result pre="in the virus particle in late endosome, and thus the" exact="infection" post="is unable to be completed. Favipiravir inhibits viral RNA"/>
  <result pre="The anti-influenza drugs NAIs and baloxavir inhibit the spread of" exact="infection" post="but allow the synthesis of genomic RNA, and the"/>
  <result pre="the production of new virus, and robust growth begins after" exact="infection" post="at a rate of four replication cycles per day."/>
  <result pre="four replication cycles per day. The course of influenza virus" exact="infection" post="was analyzed in 56 different studies with 1280 healthy"/>
  <result pre="studies with 1280 healthy participants after an experimental influenza virus" exact="infection" post="(Carrat et al., 2008). The A(H1N1) and A(H3N2) infections"/>
  <result pre="subtype of virus, and humans have neither a history of" exact="infection" post="nor immunity. Seasonal influenza mainly infects the upper respiratory"/>
  <result pre="tract, while novel influenza causes pneumonia, mainly due to an" exact="infection" post="of the pulmonary epithelium. Furthermore, unlike the presence of"/>
  <result pre="not exist for novel influenza. Therefore, the severity of the" exact="infection" post="appears to be caused by a prolonged virus growth"/>
  <result pre="influenza in seasonal influenza Oseltamivir, an NAI, has been the" exact="treatment" post="of choice for influenza infection. The emergence of a"/>
  <result pre="appears and becomes dominant during treatment. Another concern is the" exact="prevalence" post="of oseltamivir-resistant strains that was observed during the 2008"/>
  <result pre="et al., 2009), and 20.1% in Europe. In particular, a" exact="prevalence" post="of 67% (184/272) was observed in Norway, with a"/>
  <result pre="of 77 (23.4%) patients. Emergence was associated with a prolonged" exact="detection" post="of the infectious virus (median time, 180.0Â h) and"/>
  <result pre="resistant viruses may become dominant pandemic viruses. In contrast, favipiravir" exact="treatment" post="does not change the susceptibility of 57 pairs of"/>
  <result pre="of 57 pairs of viruses to favipiravir before and after" exact="treatment" post="(Takashita et al., 2016). Although the number of cases"/>
  <result pre="strains for which the effectiveness of drugs is reduced during" exact="treatment" post="or during the pandemic. 4.4 Effectiveness of favipiravir among"/>
  <result pre="of anti-RNA virus drugs: efficacy in animal models and human" exact="infection" post="5.1 The broad spectrum of the anti-RNA virus activity"/>
  <result pre="used to treat humans with diseases such as Ebola virus" exact="infection" post="(Bai et al., 2016; Jacobs et al., 2015; Sissoko"/>
  <result pre="al., 2013; Furuta, Komeno, &amp;amp; Nakamura, 2017). 5.2 Ebola virus" exact="infection" post="Concerning Ebola virus infection, the efficacy of favipiravir in"/>
  <result pre="Treatment with favipiravir from 6 to 13Â days after lethal" exact="infection" post="with Ebola virus cured all mice when the treatment"/>
  <result pre="lethal infection with Ebola virus cured all mice when the" exact="treatment" post="was started at the initiation of liver damage (elevation"/>
  <result pre="initiation of liver damage (elevation of AST and ALT) and" exact="virus detection" post="in blood. However, the administration of favipiravir from 8"/>
  <result pre="of liver damage (elevation of AST and ALT) and virus" exact="detection" post="in blood. However, the administration of favipiravir from 8"/>
  <result pre="mice died when the liver damage and viremia advanced. Early" exact="treatment" post="with favipiravir was effective, but when the disease is"/>
  <result pre="survival is limited to one of five mice, indicating that" exact="treatment" post="should be started before liver damage progresses to irreversible"/>
  <result pre="Thus, favipiravir may be able to cure an Ebola virus" exact="infection" post="in the early phase of infection, but the curative"/>
  <result pre="favipiravir used to treat a human with an Ebola virus" exact="infection" post="is 6000Â mg on the first day and 2400Â"/>
  <result pre="not been confirmed to result in infection, the probability of" exact="infection" post="was high based on previous observations, and PEP was"/>
  <result pre="compared with 540 patients as a historical control group. Favipiravir" exact="treatment" post="reduced the mortality rate in the low viral load"/>
  <result pre="historical control patients. The overall survival rate in the favipiravir" exact="treatment" post="group was higher than the control group (56.4% [22/39]"/>
  <result pre="et al., 2016). During the 2014 epidemic of Ebola virus" exact="infection" post="in West Africa, patients who were treated without favipiravir"/>
  <result pre="treated without favipiravir in the period before preparation for favipiravir" exact="treatment" post="were classified as historical controls, and the therapeutic efficacy"/>
  <result pre="The studies were conducted to compare the effectiveness of favipiravir" exact="treatment" post="between patients who were not treated in the period"/>
  <result pre="and favipiravir has been used as an emergency or compassionate" exact="treatment" post="for Lassa fever, norovirus, and rabies cases. This review"/>
  <result pre="5.4 The dose of favipiravir for influenza and Ebola virus" exact="infection" post="The antiviral activity (EC50) of favipiravir against influenza and"/>
  <result pre="day for 4Â days, and the dose for Ebloa virus" exact="infection" post="is 6000Â mg on the first day and 2400Â"/>
  <result pre="fail to replicate or produce infectious viral particles, and viral" exact="infection" post="ceases. Thus, lethal mutagenesis terminates viral infection through a"/>
  <result pre="particles, and viral infection ceases. Thus, lethal mutagenesis terminates viral" exact="infection" post="through a different mechanism than chain termination. 6.2 Increased"/>
  <result pre="number of mutations in viral genomes in favipiravir-treated cultures Favipiravir" exact="treatment" post="increases the frequency of transition (Delang et al., 2014;"/>
  <result pre="Thus, the increased mutation rates observed in response to favipiravir" exact="treatment" post="are unlikely to be due to the incorporation of"/>
  <result pre="genome. The increased rate of transition mutations observed after favipiravir" exact="treatment" post="is presumed to be due to the biased nucleotide"/>
  <result pre="sufficient to increase the ratios of mismatched transition mutations without" exact="treatment" post="with mutagens such as ribavirin. Ribavirin reduces GTP levels"/>
  <result pre="has been replaced by a resistant virus. A subsequent new" exact="infection" post="by the resistant virus has been confirmed. Therefore, we"/>
  <result pre="baloxavir resistance might be observed in clinical trials of influenza" exact="treatment" post="with oseltamivir and baloxavir with a similar number of"/>
  <result pre="of the emergence and replacement of resistant viruses during favipiravir" exact="treatment" post="in vitro and in humans indicates that the same"/>
  <result pre="could be treated effectively. 8 Organ function and lethal virus" exact="infection" post="Causes of death from severe infections may be liver"/>
  <result pre="liver failure, renal failure, respiratory failure and encephalitis. Ebola virus" exact="infection" post="seemed to be difficult for patients when they had"/>
  <result pre="be difficult for patients when they had the chance of" exact="infection" post="or fever after infection, and the amount of virus"/>
  <result pre="virus was used as an indicator of the time of" exact="infection" post="(Sissoko et al., 2016). Renal function represented by creatinine"/>
  <result pre="The factor that determines survival and death rate with favipiravir" exact="treatment" post="seems to be residual organ function at the start"/>
  <result pre="seems to be residual organ function at the start of" exact="treatment" post="in fatal infections caused by cytotoxic RNA viruses. The"/>
  <result pre="(Pomfret, Pomposelli, &amp;amp; Jenkins, 2001). It is important to begin" exact="treatment" post="before losing the recoverable function of the target organ."/>
  <result pre="the start of treatment. Time from illness onset to oseltamivir" exact="treatment" post="in avian influenza A(H7N9) virus infection is 6Â days"/>
  <result pre="illness onset to oseltamivir treatment in avian influenza A(H7N9) virus" exact="infection" post="is 6Â days (5â€&quot;9Â days), and time from illness"/>
  <result pre="days) (Li et al., 2014), indicating the importance of early" exact="diagnosis" post="and treatment. In Ebola virus infection, other than the"/>
  <result pre="control patients and patients treated with favipiravir for Ebola virus" exact="infection" post="(Bai et al., 2016; Jacobs et al., 2015; Sissoko"/>
  <result pre="avian influenza, such as A(H5N1) or A(H7N9), causes a severe" exact="infection" post="and pneumonia due to the prolonged viral replication caused"/>
  <result pre="to play a central role among anti-influenza drugs in the" exact="treatment" post="of a lethal influenza pandemic. This review helps clinicians,"/>
  <result pre="all payments were sent to the institution. References References AbdelnabiR.JochmansD.VerbekenE.NeytsJ.DelangL.Antiviral" exact="treatment" post="efficiently inhibits chikungunya virus infection in the joints of"/>
  <result pre="the institution. References References AbdelnabiR.JochmansD.VerbekenE.NeytsJ.DelangL.Antiviral treatment efficiently inhibits chikungunya virus" exact="infection" post="in the joints of mice during the acute but"/>
  <result pre="RNA polymerase complexPLoS One52010e10372 AkahoshiY.KandaJ.OhnoA.KomiyaY.GomyoA.HayakawaJ. â€¦KandaY.Acyclovir-resistant herpes simplex virus 1" exact="infection" post="early after allogeneic hematopoietic stem cell transplantation with T-cell"/>
  <result pre="With Severe InfluenzaNCT03394209https://clinicaltrials.gov/ct2/show/NCT033942092018 Cardona-OspinaJ.A.Henao-SanMartinV.Paniz-MondolfiA.E.Rodriguez-MoralesA.J.Mortality and fatality due to Chikungunya virus" exact="infection" post="in ColombiaJournal of Clinical Virology702015141526305812 CarolineA.L.PowellD.S.BethelL.M.OuryT.D.ReedD.S.HartmanA.L.Broad spectrum antiviral activity"/>
  <result pre="inhalational Rift Valley feverPLoS Neglected Tropical Diseases82014e2790 CarratF.VerguE.FergusonN.M.LemaitreM.CauchemezS.LeachS.ValleronA.J.Time lines of" exact="infection" post="and disease in human influenza: A review of volunteer"/>
  <result pre="virus in the United StatesJAMA30120091034104119255110 DieboldS.S.MontoyaM.UngerH.AlexopoulouL.RoyP.HaswellL.E. â€¦Reis e Sousa, C.Viral" exact="infection" post="switches non-plasmacytoid dendritic cells into high interferon producersNature424200332432812819664 DoyleW.J.SkonerD.P.HaydenF.BuchmanC.A.SerokyJ.T.FiremanP.Nasal"/>
  <result pre="action and selectivity of acyclovirThe American Journal of Medicine7319827136285736 EnriaD.A.MaizteguiJ.I.Antiviral" exact="treatment" post="of argentine hemorrhagic feverAntiviral Research23199423318141590 Escribano-RomeroE.JimÃ©nez de OyaN.DomingoE.SaizJ.C.Extinction of"/>
  <result pre="United States of America1152018116131161830352857 GowenB.B.JuelichT.L.SefingE.J.BraselT.SmithJ.K.ZhangL. â€¦FreibergA.N.Favipiravir (T-705) inhibits Junin virus" exact="infection" post="and reduces mortality in a Guinea pig model of"/>
  <result pre="Diseases72013e2614 GowenB.B.WestoverJ.B.MiaoJ.Van WettereA.J.RigasJ.D.HickersonB.T. â€¦WangZ.Modeling severe fever with thrombocytopenia syndrome virus" exact="infection" post="in Golden Syrian hamsters: Importance of STAT2 in preventing"/>
  <result pre="Syrian hamsters: Importance of STAT2 in preventing disease and effective" exact="treatment" post="with FavipiravirJournal of Virology912017e01942â€&quot;16 GowenB.B.WestoverJ.B.SefingE.J.Van WettereA.J.BaileyK.W.WanderseeL. â€¦FurutaY.Enhanced protection against"/>
  <result pre="of Virology912017e01942â€&quot;16 GowenB.B.WestoverJ.B.SefingE.J.Van WettereA.J.BaileyK.W.WanderseeL. â€¦FurutaY.Enhanced protection against experimental Junin virus" exact="infection" post="through the use of a modified favipiravir loading dose"/>
  <result pre="HamaY.KurokawaM.ImakitaM.YoshidaY.ShimizuT.WatanabeW.ShirakiK.Interleukin 12 is a primary cytokine responding to influenza virus" exact="infection" post="in the respiratory tract of miceActa Virologica53200923324019941386 HawmanD.W.HaddockE.Meade-WhiteK.WilliamsonB.HanleyP.W.RosenkeK. â€¦FeldmannH.Favipiravir"/>
  <result pre="of T-705 in a hamster model of yellow fever virus" exact="infection" post="in comparison with that of a chemically related compound,"/>
  <result pre="chemically related compound, T-1106Antimicrobial Agents and Chemotherapy53200920220918955536 JulanderJ.G.SmeeD.F.MorreyJ.D.FurutaY.Effect of T-705" exact="treatment" post="on western equine encephalitis in a mouse modelAntiviral Research82200916917119428608"/>
  <result pre="States of America107201088288720080770 KuA.S.ChanL.T.The first case of H5N1 avian influenza" exact="infection" post="in a human with complications of adult respiratory distress"/>
  <result pre="suppressed interleukin 1Î± production responsive to interferon and alleviated influenza" exact="infection" post="in miceJ Traditional Med131996201209 KurokawaM.KumedaC.A.YamamuraJ.KamiyamaT.ShirakiK.Antipyretic activity of cinnamyl derivatives"/>
  <result pre="Kakkon-to, a herbal medicine, on the early stage of influenza" exact="infection" post="in miceAntiviral Research56200218318812367723 KurokawaM.WatanabeW.ShimizuT.SawamuraR.ShirakiK.Modulation of cytokine production by 7-hydroxycoumarin"/>
  <result pre="production by 7-hydroxycoumarin in vitro and its efficacy against influenza" exact="infection" post="in miceAntiviral Research85201037338019913056 KurokawaM.YamamuraJ.LiZ.SatoH.HitomiN.TatsumiY.ShirakiK.Antipyretic activity of gingyo-san, a traditional"/>
  <result pre="Chemotherapy15200428128515535050 LaiS.QinY.CowlingB.J.RenX.WardropN.A.GilbertM. â€¦YuH.Global epidemiology of avian influenza A H5N1 virus" exact="infection" post="in humans, 1997-2015: A systematic review of individual case"/>
  <result pre="2007-08 seasonEmerging Infectious Diseases15200955256019331731 MemoliM.J.AthotaR.ReedS.CzajkowskiL.BristolT.ProudfootK. â€¦TaubenbergerJ.K.The natural history of influenza" exact="infection" post="in the severely immunocompromised vs nonimmunocompromised hostsClinical Infectious Diseases58201421422424186906"/>
  <result pre="orally administered T-705 pyrazine analog on lethal West Nile virus" exact="infection" post="in rodentsAntiviral Research80200837737918762216 NaesensL.GuddatL.W.KeoughD.T.van KuilenburgA.B.MeijerJ.Vande VoordeJ.BalzariniJ.Role of human hypoxanthine"/>
  <result pre="T-705 (favipiravir)Molecular Pharmacology84201361562923907213 National Kidney FoundationHemodialysis2019National Kidney FoundationNew Yorkhttps://www.kidney.org/atoz/content/hemodialysis OestereichL.LudtkeA.WurrS.RiegerT.Munoz-FontelaC.GuntherS.Successful" exact="treatment" post="of advanced Ebola virus infection with T-705 (favipiravir) in"/>
  <result pre="FoundationHemodialysis2019National Kidney FoundationNew Yorkhttps://www.kidney.org/atoz/content/hemodialysis OestereichL.LudtkeA.WurrS.RiegerT.Munoz-FontelaC.GuntherS.Successful treatment of advanced Ebola virus" exact="infection" post="with T-705 (favipiravir) in a small animal modelAntiviral Research1052014172124583123"/>
  <result pre="Tropical Diseases82014e2804 OmotoS.SperanziniV.HashimotoT.NoshiT.YamaguchiH.KawaiM. â€¦CusackS.Characterization of influenza virus variants induced by" exact="treatment" post="with the endonuclease inhibitor baloxavir marboxilScientific Reports82018963329941893 PhilpottD.C.E.NolanM.S.EvertN.MayesB.HesalroadD.FonkenE.MurrayK.O.Acute and"/>
  <result pre="infectionFrontiers in Immunology102019216131572376 RaabeV.N.KannG.RibnerB.S.MoralesA.VarkeyJ.B.MehtaA.K. â€¦Emory Serious Communicable DiseasesU.Favipiravir and ribavirin" exact="treatment" post="of epidemiologically linked cases of Lassa feverClinical Infectious Diseases65201785585929017278"/>
  <result pre="broad-spectrum antiviral favipiravir protects Guinea pigs from lethal Lassa virus" exact="infection" post="post-disease onsetScientific Reports520151477526456301 SangawaH.KomenoT.NishikawaH.YoshidaA.TakahashiK.NomuraN.FurutaY.Mechanism of action of T-705 ribosyl"/>
  <result pre="WettereA. â€¦GowenB.B.Favipiravir (T-705) protects against peracute Rift Valley fever virus" exact="infection" post="and reduces delayed-onset neurologic disease observed with ribavirin treatmentAntiviral"/>
  <result pre="(H5N1) virus infections in miceAntimicrobial Agents and Chemotherapy51200784585117194832 SissokoD.LaouenanC.FolkessonE.Mâ€™LebingA.B.BeavoguiA.H.BaizeS. â€¦GroupJ.S.Experimental" exact="treatment" post="with Favipiravir for Ebola virus disease (the JIKI trial):"/>
  <result pre="SmitherS.J.EastaughL.S.StewardJ.A.NelsonM.LenkR.P.LeverM.S.Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus" exact="infection" post="in a mouse modelAntiviral Research104201415315524462697 SpicklerA.R.Eastern, Western and Venezuelan"/>
  <result pre="anti-influenza drugActa Virologica612017485528105854 TaniH.FukumaA.FukushiS.TaniguchiS.YoshikawaT.Iwata-YoshikawaN. â€¦SaijoM.Efficacy of T-705 (Favipiravir) in the" exact="treatment" post="of infections with lethal severe fever with thrombocytopenia syndrome"/>
  <result pre="triphosphate accumulation in Escherichia coliDNA Repair (Amst)420051450145616207537 WhitleyR.J.HaydenF.G.ReisingerK.S.YoungN.DutkowskiR.IpeD. â€¦WardP.Oral oseltamivir" exact="treatment" post="of influenza in childrenThe Pediatric Infectious Disease Journal20200112713311224828 WongJ.P.ChristopherM.E.ViswanathanS.KarpoffN.DaiX.DasD."/>
  <result pre="for patients with severe fever with thrombocytopenia syndromeIn UMIN000022398https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R0000331942016 ZhuW.ZhangZ.HeS.WongG.BanadygaL.QiuX.Successful" exact="treatment" post="of Marburg virus with orally administrated T-705 (Favipiravir) in"/>
 </snippets>
</snippetsTree>
